Comparison of adult pre-B ALL engraftment by either unconditioned (−TBI) or 2.5-Gy preconditioned (+TBI) xenotransplantation methods
| Major cytogenetic group . | No. of engrafting samples . | P . | |
|---|---|---|---|
| +TBI . | −TBI . | ||
| Normal/other | 7/7 | 0/6 | .0006 |
| t(9;22) | 3/3 | 0/4 | .0286 |
| t(4;11) | 1/2 | 2/3 | NS |
| Proportion of engrafting samples: % leukemic engraftment Mean no. of weeks to disease manifestation (range)* | |||
| 11/12 | 2/13 | .0394 | |
| 81.9 ± 5.4 | 96.4 ± 1.4 | NS | |
| 15.9 (5.9-29.7) | 27.7 (26.9-29.3) | .0231 | |
| Major cytogenetic group . | No. of engrafting samples . | P . | |
|---|---|---|---|
| +TBI . | −TBI . | ||
| Normal/other | 7/7 | 0/6 | .0006 |
| t(9;22) | 3/3 | 0/4 | .0286 |
| t(4;11) | 1/2 | 2/3 | NS |
| Proportion of engrafting samples: % leukemic engraftment Mean no. of weeks to disease manifestation (range)* | |||
| 11/12 | 2/13 | .0394 | |
| 81.9 ± 5.4 | 96.4 ± 1.4 | NS | |
| 15.9 (5.9-29.7) | 27.7 (26.9-29.3) | .0231 | |
NS, nonsignificant.
The number of samples with leukemic engraftment (CD45+/CD19+ > 0.01%) over the total number injected is shown.